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The aim of this study was to conduct a national survey to evaluate the recent endoscopic treatment and drug therapy of peptic
ulcer bleeding (PUB) patients and to compare practices in high and low case volume Hungarian workplaces. A total of 62
gastroenterology units participated in the six-month study. A total of 3033 PUB cases and a mean of 8.15 ± 3.9 PUB cases per
month per unit were reported. In the 23 high case volume units (HCV), there was a mean of 12.9± 5.4 PUB cases/month, whereas
in the 39 low case volume units (LCV), a mean of 5.3 ± 2.9 PUB cases/month were treated during the study period. In HCV
units, endoscopic therapies for Forrest Ia, Ib, and IIa ulcers were significantly more often used than in LCV units (86% versus
68%; P = 0.001). Among patients with stigmata of recent haemorrhage (Forrest I, II), bolus + continuous infusion PPI was given
significantly more frequently in HCV than in LCV units (49.6% versus 33.2%; P = 0.001). Mortality in HCV units was less than in
LCV units (2.7% versus 4.3%; P = 0.023). The penetration of evidence-based recommendations for PUB management is stronger
in HCV units resulting lower mortality.
1. Introduction
Acute upper gastrointestinal bleeding (UGIB) is a common
medical emergency situation. Peptic ulcer bleeding (PUB)
is responsible for almost half of the cases of UGIB [1, 2].
Despite advances in diagnosis and treatment during the
recent years, rebleeding occurs in about 10–30% after pri-
mary haemostasis, and the mortality is still around 5–10%
[1–5]. The appropriate management for patients with acute
gastroduodenal ulcer bleeding has been established over the
last two decades in a number of randomised controlled trials
and in several guidelines [6–13]. Recommendations for the
management of PUB were also published in Hungary [14].
The most important elements of these recommendations
were to organize and maintain a 24-hour emergency
endoscopy services for UGIB patients, to use the Forrest clas-
sificaton for PUB patients, endoscopic haemostatic therapy
preferably with a combined methods obligatory in cases with
active bleeding, and strongly recommended in ulcer cases
with visible vessels and also with adherent clots. Acid-sup-
pressant therapy was recommended by i.v. proton-pump
inhibitors following endoscopic haemostasis for 72 hours in
ulcer cases with stigmata of recent haemorrhage.
The primary aims of our work were to conduct a national
survey to evaluate the use of recommendations and guide-
lines in the daily routine management of PUB and also to
compare practices and patient outcome data in high and low
case volume workplaces.
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Table 1: Main points of the questionnaire for upper GI bleeders in
Hungary.
(1) Structural and activity data
(i) Practice of care
(a) Gastroenterology unit
(b) Surgical unit
(c) Number of endoscopiests doing emergency endoscopy
(ii) Number of bleeders per month
(a) UGIB cases per month
(b) PUB cases per month
(2) Emergency endoscopy findings
(i) Source of bleeding
(ii) Number of ulcers and characteristics according to the
Forrest classification
(3) Endoscopic haemostatic therapy
(i) Indication for endoscopic therapy
(ii) Method of haemostatic therapy in diﬀerent Forrest classes
(a) Injection, substance of injection, mono; or in
combination
(b) Thermal
(c) Clip
(d) Combination therapy; components of combination
(4) Acid-suppressant therapy in diﬀerent Forrest classes
(i) Substance for acid suppression; i.v. PPI or i.v. H2RA
(ii) Method of i.v. PPI
(a) Standard PPI dosage
(b) Bolus + PPI infusion
(5) Patient outcome data
(i) Rebleeding rate
(ii) Need for surgery
(iii) Bleeding-related mortality
2. Material andMethods
The survey was designed to evaluate the diﬀerent steps of
the management procedure of PUB. Additionally, some basic
patient outcome data were also collected (Table 1).
A database of all Hungarian gastroenterology depart-
ments performing endoscopy and treating acute GI bleeding
was available on the basis of the address list of the Endoscopy
section of the Hungarian Society of Gastroenterology. The
questionnaires were distributed and collected monthly by
specially trained research assistants in those 62 gastroentero-
logical workplaces (GI units) that responded positively to
participate in the study. These 62 GI units from 39 cities
account for 71% of the GI workplaces existing in Hungary.
To ensure the validity of the collected data, the research
assistants with the participation of the local study coor-
dinator endoscopists reviewed and monitored each month
all endoscopy reports and patient files of the endoscopy
units searching for all documented data of UGIB patients.
The aim of this rigorous data monitoring protocol was to
collect reasonably high-quality data of current practices.
All data were entered electronically and downloaded into
a central repository on a monthly basis. In Hungary, only
gastroenterologists or surgeons, when they have taken at least
a two-year endoscopy training course, may perform upper or
lower endoscopy.
2.1. Statistical Analysis. Data were collected and analysed
using the statistical package SPSS version 11.0 (SPSS In.
Chicago, IL, USA). Descriptive statistics were used to analyse
and report the data. The chi-squared and the Fisher tests were
used to determine diﬀerences between low and high case
volume GI units and also for the analysis of two and multi-
dimensional contingency tables. Multiple logistic regression
was applied to evaluate the independent relations of selected
factors for the use of combined haemostatic methods fol-
lowed by bolus plus continuous infusion of PPI. The signifi-
cance threshold was set at P < 0.05.
3. Results
3.1. General Data and Case Volume Diﬀerences. A total of 62
GI units provided data by completing the questionnaires
in a six-month period during 2009 and 2010. A 24-hour
emergency endoscopy service was guaranteed in 90% (n =
54) of the workplaces, and specialised endoscopy nurses were
available in 85% (n = 51) for 24 hours. A total of 6,473 acute
upper GI bleedings including 3,033 (46.9%) PUB cases were
reported. Of the responded PUB cases, 89.2% were managed
by gastroenterologists and 10.8% by surgeons.
A mean of 17.4± 8.2 UGIB and 8.15± 3.9 PUB cases per
month per unit were reported, respectively. There were 23
units that reportedmore than 8.15 PUB cases permonth, and
the remaining 39 units had fewer PUB cases monthly than
this mean. This selection oﬀered the possibility to divide the
reporting GI units into high case volume (HCV) and low case
volume (LCV) units according to the monthly mean of ulcer
bleeders of which they took care. In the 23 HCV units, a total
of 1,789 PUB cases (mean 12.9±5.4 cases/month), whereas in
the 39 LCV units, a total of 1,244 PUB cases (mean: 5.3± 2.9
cases/month) were managed during the study period. These
data reflect that the HCV units had more than twice as many
PUB cases and experiences per month compared to the LCV
workplaces.
The Forrest classification was uniformly used both in
HCV and LCV units. The proportion of emergency endo-
scopy findings according to the Forrest classification were
similar comparing results obtained from HCV and LCV
workplaces (Figure 1). The ratio of high-risk lesion bleeders
(Forrest Ia-IIa) was also similar (n = 717; 40%) in HCV and
LCV (n = 479; 38.5%) units.
3.2. Endoscopic Haemostatic Therapy. Endoscopic haemo-
static therapy was given for ulcers with spurting bleeding
(Forrest Ia), oozing bleeding (Ib), nonbleeding visible vessels
(IIa), adherent clot (IIb), black haematin-covered ulcer base
(IIc), and clean ulcer base (III) in, respectively, 94%, 83%,
69%, 43%, 15%, and 4% of all responded PUB cases. In HCV
units, endoscopic therapy was significantly more often used
in Forrest Ia, Ib and Forrest IIa cases (n = 613; 85.4%) com-
pared with similar Forrest grade cases in LCV units (n = 327;
68.2%) (Table 2).
The most frequently used haemostatic treatment modal-
ity either in mono or in combination was injection with
diluted (1 : 10.000) epinephrine (n = 1108; 92.6%). As
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Figure 1: Proportion of bleeding ulcers according to Forrest classification in high case volume (HCV) and low case volume (LCV) units.
Table 2: Comparison of selected items in high and low case volume units.
HCV units (n = 23) LCV units (n = 39) P value
Number of PUB cases 1789 1244 not applicable
Mean number of PUB cases/endoscopists/month 3.2 ± 1.1 2.4 ± 0.9 ns
Item % (n) % (n)
Endoscopic haemostatic treatment
In Forrest Ia, Ib, and IIa 86 (613) 68 (327) 0.001
In Forrest IIb 45 (154) 39 (97) 0.015
Endoscopic treatment modality in Forrest Ia, Ib, and IIa
Injection monotherapy 46 (285) 65 (311) 0.001
Haemoclip or thermocoagulation monotherapy 20 (121) 16 (51) 0.002
Combination 34 (207) 19 (61) 0.001
Acid-suppressant therapy after endoscopy with i.v. PPI
Overall 79 (1413) 81 (1002) 0.490
In patients with Forrest I-II
With standard dosages 28 (494) 48 (601) 0.001
With bolus + continuous PPI 50 (888) 33 (415) 0.001
Rebleeding rate 10.1 (179) 9.5 (118) 0.680
Need for surgery 5.1 (92) 6.4 (79) 0.181
Mortality
Overall 2.7 (48) 4.3 (53) 0.023
In Forrest Ia, Ib 6.8 (29) 7.6 (21) 0.791
a combination treatment generally, injection and haemoclips
or injection and coagulation were combined. For high-
risk ulcers (Forrest Ia, Ib, IIa), the combined haemostatic
attempts were significantly more frequently used in HCV
than in LCV units (n = 207; 34% versus n = 61; 19%;
P < 0.01), whereas the oppositeresult was detected regarding
injection monotherapies, which were significantly more
often used in LCV than in HCV units (n = 311; 65% versus
n = 285; 46%; P < 0.001) (Table 2).
3.3. Acid-Suppressant Therapy. In our questionnaire we
asked only for the postendoscopy acid-suppressive drugs
because the preendoscopy i.v. PPI treatment policy was not
yet established at the time of the survey.
4 Gastroenterology Research and Practice
Table 3: Multiple logistic regression module of selected factors for the use of combined haemostatic methods followed by bolus plus
continuous infusion of PPI in high-risk ulcer patients.
Odds ratio P value 95% CI
24-hour emergency endoscopy service available 0.82 0.738 0.92–1.12
Gastroenterology versus surgical unit 0.99 0.767 0.96–1.03
University versus municipal hospital 0.73 0.684 0.13–2.82
Mean number of endoscopiests per unit doing emergency endoscopy, <3 versus ≥3 2.28 0.078 0.91–5.76
Mean number of UGIB cases per month, <8.15 versus ≥8.15 5.48 0.012 1.88–18.42
Acid-suppressive drugs following the endoscopy were
administered intravenously (i.v.) in the majority of PUB
cases (n = 2516; 83.0%),mostly using PPI (n = 2425; 79.9%)
and only seldomly using H2-receptor antagonists (n = 91;
3.0%). In less than half of all PUB cases (n = 1095;
45.2%), i.v. PPI was given in standard dosages twice or three
times daily, whereas bolus PPI followed by a continuous
infusion of 8mg PPI per hour was used slightly more often
(n = 1301; 53.6%). Among patients with stigmata of recent
haemorrhage (Forrest I-II), bolus + continuous infusion PPI
was given significantly more frequently in HCV than in LCV
units (n = 888; 49.6% versus n = 413; 33.2%; P < 0.001)
(Table 2).
According tomultivariate analysis, the monthly PUB case
volume of units was the only significant predictor factor for
the use of best evidence combined endoscopic haemostasis
followed by bolus plus infusion PPI in high-risk ulcers
(Table 3).
3.4. Clinical Outcome. Overall rebleeding rates were compa-
rable in HCV (n = 179; 10.1%) and in LCV (n = 118; 9.5%)
units. Also rebleeding rates in high-risk ulcers (Forrest Ia-IIa)
were similar in HCV (n = 141; 19.7%) and in LCV (n = 63;
19%) units.
Because of persistent bleeding or endoscopically untreat-
able severe rebleeding, surgery was needed slightly more fre-
quently in LCV (n = 79; 6.4%) than in HCV (n = 92; 5.1%)
units. In cases with endoscopically untreatable spurting
bleedings, an immediate surgery was significanly (P < 0.05)
more often warranted in LCV (n = 29; 49.2%) compared to
HCV (n = 36; 32.1%) units.
The bleeding-related mortality rate of all PUB patients
was 3.3% (n = 101). Mortality in HCV units (n = 48;
2.7%) was significantly (P = 0.023) less than the mortality
in LCV units (n = 53; 4.3%). Those patients with initial
spurting (Forrest Ia) and oozing (Forrest Ib) bleedings had
higher mortality rate (n = 21; 7.6%) in the LCV than in HCV
units (n = 29; 6.8%), but this diﬀerence was not significant
(Table 2).
4. Discussion
This is the first clinical inquiry conducted in Hungary illus-
trating the daily routine endoscopic and pharmacological
management of PUB. Similar surveys were performed pre-
viously in the Netherlands, France, and recently in Germany
with the response rates of 73%, 34%, and 49%, respectively,
positioning our survey with a 71% response rate in between
these other surveys [15–17].
In the present study, unlike the previous surveys, epi-
demiological and practice diﬀerences of high case volume
and low case volume units were compared as a primary aim.
Nevertheless, the high and low volumes of endoscopy units
were not a priori and numerically defined in the question-
naires but just based on the collected data reflecting mean
number of PUB cases per month per units. This comparison
was rational because in HCV units, more than twice as many
PUB cases per month were treated compared to the LCV
units; one may suspect that the diﬀering volumes would alter
the daily practices.
In our study, entirely emergency or early endoscopy cases
with endoscopic procedures within the first 24 hours after the
admissions were reported [18].
The Forrest classification is the most frequently used
bleeding ulcer classification system worldwide [19, 20]. The
Forrest classification was used in 100% of the reported cases,
both in HCV and LCV units.
This inquiry shows a strong similarity in the proportion
of ulcers according to the Forrest grades when comparing
the data of HCV and LCV units. Ulcers with active bleeding
(Forrest Ia, Ib) occurred in 23.8% in HCV units and in
22.1% in LCV units, whereas the proportion of ulcers with
nonbleeding visible vessels (Forrest IIa) were almost identical
(16.5% versus 16.6%).
Previous guidelines and conference reports recom-
mended that all ulcers classified as Forrest Ia–IIb should be
treated endoscopically [5, 14, 21]. A new meta-analysis by
Laine and McQuaid revised the indication of endoscopic
therapy in those Forrest IIb lesions with clots that resist vig-
orous rinsing [22]. By the modified recommendation, only
patients with severe comorbidities should receive endoscopic
therapy, and PPI therapy may be suﬃcient.
In our survey, actively bleeding ulcers and ulcers with
nonbleeding visible vessels were treated endoscopically with
a surprisingly low frequency in LCV units because roughly
one third of these cases were left untreated. Although these
results are not much inferior to the France survey data [16],
where Forrest IIa patients were endoscopically treated in
79%, we may draw the conclusion that mainly in LCV units
either the technical facilities or the penetration of current
guidelines are suboptimal.
The combination of haemostatic methods was used
rather seldomly (34%) even in HCV units in our survey.
Despite the fact that combination haemostatic therapy was
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used significantly more often in HCV units than in LCV
units, one should conclude that for closing international
standards, the combined haemostatic methods should be
more promoted and also resourced [23].
According to current guidelines, intravenous bolus fol-
lowed by continuous-infusion PPI should be used in patients
with stigmata having undergone successful endoscopic ther-
apy [5, 24, 25]. However, only 80% of the PUB cases were
treated by i.v. PPI in our survey, which is a lower value
compared to any other national inquiry on the same topic.
Moreover, the best evidence 72-hour PPI administration
policy [12, 13, 26] was followed in less than every other
patient in both types of units. This deficit of a PPI treatment
policy in our study may reflect the attitude of more focus on
endoscopic therapy and less interest in medical treatment in
the management of PUB patients.
When comparing HCV and LCV units, significant dif-
ferences existed in some items of PUB management. In
particular, haemostatic therapy with combination and PPI
treatment by continuous infusion were used more frequently
in those units with more PUB cases. Multivariate analysis
showed that the only significant predictor factor for the use
of these evidence-based standards of care was the monthly
PUB case volume in the units. Some of these diﬀerences
may be explained by poorer training or by less experience in
lower case workplaces. Additionally, certain anomalies could
be explained by the lack of financial resources in low case
units, which mostly exist in smaller hospitals.
It is important to note that the financial reimbursement
for haemostatic endoscopy has been rather low and inbal-
anced up to recently in Hungary which may be one of the
reasons why in smaller hospitals the adherence to guidelines
were suboptimal.
The main clinical outcomemeasures regarding the whole
PUB cohort of this survey are comparable to previously
published large databases [2, 27, 28]. In parallel with the
trend that HCV units were closer to the best clinical practice
consequences was seen onmajor clinical outcomes. Although
rebleeding rates and the need for surgery were similar in the
two units types, a significantly lower mortality rate was seen
in HCV units compared to that in LCV units.
Considering these data, the question arises whether it
is reasonable to manage PUB patients in LCV units or to
centralize emergencies in HCV units is appropriate for many
aspects like better oﬀer of experienced endoscopiests and
optimal utilization of financial sources are available.
Our study has some limitations similarly to other surveys
dealing with PUB management in the daily routine. It is
uncertain how has the registration influenced the results, and
also there is no data whether the registration per se increased
compliance with the guidelines. Although the inherent
limitations of the survey, the comparison of diﬀerent case
volume workplaces adds some new knowledge.
In conclusion, our hypothesis that PUB case volumes
have an eﬀect on managing standards was mostly confirmed.
Penetration of national recommendation and international
guidelines is stronger in HCV units than in LCV units. Lower
mortality of PUB patients in HCV units might be associated
with better standards of care in those units. The results of
this study could motivate medical societies and authorities
to discuss whether PUB management needs further quality
assurance eﬀorts and better resources to improve daily
practices.
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